Zentalis Pharmaceuticals (NASDAQ:ZNTL) Given “Neutral” Rating at Wedbush

Wedbush reissued their neutral rating on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note released on Friday,RTT News reports. Wedbush currently has a $4.00 price target on the stock.

Other equities analysts also recently issued reports about the stock. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a report on Friday, November 15th. Guggenheim dropped their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research note on Friday, November 15th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Zentalis Pharmaceuticals Stock Down 3.5 %

Shares of ZNTL stock opened at $2.22 on Friday. Zentalis Pharmaceuticals has a 52-week low of $2.13 and a 52-week high of $18.07. The company has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $3.34.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.36. Equities research analysts predict that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC lifted its position in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares in the last quarter. Primecap Management Co. CA lifted its holdings in Zentalis Pharmaceuticals by 21.6% during the 3rd quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after purchasing an additional 265,690 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Zentalis Pharmaceuticals by 152.6% during the 2nd quarter. Renaissance Technologies LLC now owns 661,682 shares of the company’s stock worth $2,706,000 after purchasing an additional 399,745 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Zentalis Pharmaceuticals by 138.5% in the 3rd quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock worth $2,240,000 after purchasing an additional 353,384 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in Zentalis Pharmaceuticals by 126.3% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after buying an additional 127,868 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.